Atara Biotherapeutics Presents New MRI And Updated Open-Label Extension Data From Phase 1 Study Of ATA188 In Progressive Multiple Sclerosis At ECTRIMS 2022 October 26-28
October 26, 2:07 AM
Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients Treated with ATA188 that Achieved CDI
October 24, 5:37 AM
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
October 24, 4:19 AM
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session.
Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact
September 29, 7:30 AM
Atara Biotherapeutics Inc (NASDAQ:ATRA) announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel) for Epstein-Barr…
September 29, 6:55 AM
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European Journal of Heart Failure.
September 29, 5:09 AM
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Atara Biotherapeutics To Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel Commercialization Agreement With Pierre Fabre; Atara To Receive Additional $30M Upon European Commission Approval And Filing Of Tab-Cel
September 28, 4:03 PM
Atara to Receive Additional USD 30 Million Upon European Commission (EC) Approval and Filing of Tab-cel® Marketing Authorization Transfer to Pierre Fabre Responses Submitted to European Medicines